Baiyun Mountain (00874): Xingzhu Pharmaceutical's “Pharmaceutical Production License” has been cancelled

Zhitong Finance App News, Baiyunshan (00874) issued an announcement. Recently, the Guangdong Drug Administration issued the “Notice of Cancellation of the Guangdong Drug Administration (No.<药品生产许可证> 102 of 2025)”. Guangzhou Baiyunshan Xingzhu Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”), a subsidiary of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Xingzhu Pharmaceutical”), has cancelled the “Pharmaceutical Production License”. The reason for this cancellation is that Xingzhu Pharmaceutical has adjusted its production and operation business, and the “Pharmaceutical Production License” of Chinese medicine tablets is Once the validity period of the “License” expires, it is not possible to apply for a new license.

Xingzhu Pharmaceutical has adjusted its production and operation business, focusing its main business on the pre-processing and extraction business of traditional Chinese medicine. After the “Pharmaceutical Production License”, which is the scope of production of Chinese medicine tablets, expires, it will not apply for a new license, and the “Pharmaceutical Production License” will be cancelled. Xingzhu Pharmaceutical's Chinese medicine tablet business did not generate revenue in 2024.